The Kidney Finally Gets a Seat at the Heart Risk Table
✓Medically Reviewed by Dr. Şekip Altunkan on Nov 2, 2026.
Key Takeaways
The 2025 AHA/ACC high blood pressure guideline formally adopts the PREVENT calculator, which integrates kidney and metabolic health into cardiovascular risk prediction, while reinforcing a blood pressure target of less than 130/80 mm Hg. A nephrology working group largely endorses the guideline for non-dialysis-dependent chronic kidney disease, while highlighting key areas where evidence remains sparse and kidney patients require nuanced clinical vigilance.
The Organ Cardiovascular Risk Calculators Left Behind
Consider a 58-year-old man with mild renal impairment, a blood pressure hovering at 136/84 mm Hg, and no personal history of myocardial infarction or stroke. For decades, the risk assessment engines his physician relied upon completely ignored his kidneys. Although nephrologists have long recognized chronic kidney disease (CKD) as an independent driver of cardiovascular pathology, this reality never made it into the mathematical equations dictating the aggressiveness of therapy[1]. This blind spot carried grave implications: CKD afflicts an estimated 37 million adults in the United States, and elevated blood pressure serves as the primary catalyst propelling these individuals toward end-stage kidney disease, major adverse cardiovascular events, and premature death[2].
The 2025 American Heart Association and American College of Cardiology (AHA/ACC) guideline closes this critical gap. Replacing legacy models, the newly minted PREVENT calculator unifies cardiac, renal, and metabolic health into a single risk paradigm, all while steadfastly upholding the blood pressure threshold of less than 130/80 mm Hg[1].
How Nephrology Specialists Interpret the New Mandate
Because these recommendations penetrate the core of nephrology practice, the Kidney Disease Outcomes Quality Initiative (KDOQI)—the clinical guidance arm of the National Kidney Foundation—convened an expert working group to dissect the guideline line by line. This initiative…
ŞA
Medically reviewed by
Dr. Şekip Altunkan
Dr. Şekip Altunkan is an internal medicine specialist with extensive clinical experience. He trained at Hacettepe University Faculty of Medicine and later served as an Associate Professor in Internal Medicine. He founded and led the Metropol Internal Medicine and Hypertension Clinic in Ankara, pioneering non-invasive Electron Beam Tomography (EBT) cardiac imaging, arterial-stiffness measurement, and nationwide Holter monitoring. He currently practices at his private clinic in Ankara, focusing on hypertension, vascular health, cholesterol, diabetes and heart disease. He has published widely in national and international journals, serves as a peer reviewer for several international journals, and is the author of the book "Questions and Answers on Hypertension."
